Research Tracker›Biomarker Atlas›Long COVID›Tumor Necrosis Factor-α (TNF-α)

Tumor Necrosis Factor-α (TNF-α) in Long COVID

In Long COVID (PASC, Post-Acute Sequelae of COVID-19), published studies report higher levels of Tumor Necrosis Factor-α (TNF-α), also described as Pro-inflammatory cytokine, than in healthy controls, recovered individuals without persistent symptoms. Symptom domains tied to this marker in the source include fatigue, myalgia. The evidence summarised here comes from Lai et al. 2023; Saito et al. 2024 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedInflammatoryLOINC 3074-8

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asPro-inflammatory cytokine
Compared againstHC, R (healthy controls, recovered individuals without persistent symptoms)
Associated symptomsFatigue, myalgia
Test typeBlood test (serum / plasma / whole blood)
LOINC code3074-8
SourceLai et al. 2023; Saito et al. 2024 — doi:10.3389/fimmu.2024.1341843
Condition atlasLong COVID Biomarker Atlas

Other conditions where Tumor Necrosis Factor-α (TNF-α) is reported

See the cross-condition hub: Tumor Necrosis Factor-α (TNF-α) across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Tumor Necrosis Factor-alpha (TNF-α) (10 registered trials use a matching outcome measure).

Clinical trials using Tumor Necrosis Factor-α (TNF-α) as an outcome

2 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Commercial test availability

Tumor Necrosis Factor-α (TNF-α) — commercial laboratory test. Often send-out; availability varies by region.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Inflammatory markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Tumor Necrosis Factor-α (TNF-α) high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher Tumor Necrosis Factor-α (TNF-α) in Long COVID than in healthy controls, recovered individuals without persistent symptoms. Source: Lai et al. 2023; Saito et al. 2024.

What symptoms is Tumor Necrosis Factor-α (TNF-α) associated with in Long COVID?

The cited literature associates this marker with Fatigue, myalgia. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Tumor Necrosis Factor-α (TNF-α)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 3074-8. Commercial laboratories such as Quest Diagnostics, LabCorp list an orderable assay.

Is one abnormal Tumor Necrosis Factor-α (TNF-α) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Tumor Necrosis Factor-α (TNF-α) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Tumor Necrosis Factor-α (TNF-α) specific to Long COVID?

No. The same marker is also reported in Gulf War Illness, ME/CFS in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Tumor Necrosis Factor-α (TNF-α) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/tumor-necrosis-factor-alpha-tnf-alpha.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.